About OHR Pharmaceutical (NASDAQ:OHRP)
OHR Pharmaceutical, Inc., a clinical-stage pharmaceutical company, focuses on the development of novel therapies for the treatment of ophthalmic diseases. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine in combination with Lucentis injections, which completed Phase II clinical trials for the treatment of retinal diseases, including wet form of age-related macular degeneration, retinal vein occlusion, and diabetic retinopathy. It is also developing a sustained release ocular drug delivery platform technology. OHR Pharmaceutical, Inc. is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OHRP
CUSIPN/A
Phone212-682-8452
Debt
Debt-to-Equity RatioN/A
Current Ratio2.46%
Quick Ratio2.46%
Price-To-Earnings
Trailing P/E Ratio-0.45
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.41 per share
Price / Book0.56
Profitability
EPS (Most Recent Fiscal Year)($0.53)
Net Income$-23,810,000.00
Net MarginsN/A
Return on Equity-94.42%
Return on Assets-75.99%
Miscellaneous
Employees4
Outstanding Shares56,470,000
OHR Pharmaceutical (NASDAQ:OHRP) Frequently Asked Questions
What is OHR Pharmaceutical's stock symbol?
OHR Pharmaceutical trades on the NASDAQ under the ticker symbol "OHRP."
How were OHR Pharmaceutical's earnings last quarter?
OHR Pharmaceutical Inc (NASDAQ:OHRP) announced its quarterly earnings data on Thursday, February, 15th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.07). View OHR Pharmaceutical's Earnings History.
What price target have analysts set for OHRP?
2 equities research analysts have issued 1-year target prices for OHR Pharmaceutical's stock. Their forecasts range from $7.00 to $10.00. On average, they expect OHR Pharmaceutical's stock price to reach $8.50 in the next year. View Analyst Ratings for OHR Pharmaceutical.
Who are some of OHR Pharmaceutical's key competitors?
Some companies that are related to OHR Pharmaceutical include Tonix Pharmaceuticals (TNXP), Regenerx Biopharmaceuticals (RGRX), Akari Therapeutics (AKTX), DelMar Pharmaceuticals (DMPI), ContraVir Pharmaceuticals (CTRV), AEterna Zentaris (AEZS), IntelliPharmaCeutics Intl (IPCI), Cellectar Biosciences (CLRB), ESSA Pharma (EPIX), Bio-Path (BPTH), Sonoma Pharmaceuticals (SNOA), Xenetic Biosciences (XBIO), Cyclacel (CYCC), Fibrocell (FCSC), Prana Biotechnology (PRAN), Ritter Pharmaceuticals (RTTR), Soligenix (SNGX) and Onconova Therapeutics (ONTX).
Who are OHR Pharmaceutical's key executives?
OHR Pharmaceutical's management team includes the folowing people:
- Dr. Jason Scott Slakter, CEO, Pres & Director (Age 60)
- Mr. Samuel Backenroth, Chief Financial Officer and VP of Bus. Devel. (Age 34)
- Dr. Glenn L. Stoller M.D., Chief Scientific Officer (Age 54)
- Dr. Peter K. Kaiser M.D., Head of Product Devel.
- Dr. Marlene Modi Ph.D., Head of Preclinical and Regulatory Affairs
Has OHR Pharmaceutical been receiving favorable news coverage?
News headlines about OHRP stock have trended somewhat positive this week, Accern reports. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. OHR Pharmaceutical earned a daily sentiment score of 0.07 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 45.82 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
How do I buy shares of OHR Pharmaceutical?
Shares of OHRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OHR Pharmaceutical's stock price today?
One share of OHRP stock can currently be purchased for approximately $0.23.
How big of a company is OHR Pharmaceutical?
OHR Pharmaceutical has a market capitalization of $13.33 million. The biotechnology company earns $-23,810,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis. OHR Pharmaceutical employs 4 workers across the globe.
How can I contact OHR Pharmaceutical?
OHR Pharmaceutical's mailing address is 800 THIRD AVENUE 11TH FLOOR, NEW YORK NY, 10022. The biotechnology company can be reached via phone at 212-682-8452 or via email at [email protected]
MarketBeat Community Rating for OHR Pharmaceutical (OHRP)
MarketBeat's community ratings are surveys of what our community members think about OHR Pharmaceutical and other stocks. Vote "Outperform" if you believe OHRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OHRP will underperform the S&P 500 over the long term. You may vote once every thirty days.
OHR Pharmaceutical (NASDAQ:OHRP) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for OHR Pharmaceutical in the last 12 months. Their average twelve-month price target is $8.50, suggesting that the stock has a possible upside of 3,595.65%. The high price target for OHRP is $10.00 and the low price target for OHRP is $7.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.50 | 2.50 | 2.50 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $8.50 | $8.50 | $8.50 | $10.00 |
| Price Target Upside: | 3,595.65% upside | 320.79% upside | 320.79% upside | 1,539.34% upside |
OHR Pharmaceutical (NASDAQ:OHRP) Consensus Price Target History
OHR Pharmaceutical (NASDAQ:OHRP) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
OHR Pharmaceutical (NASDAQ:OHRP) Earnings History and Estimates Chart
OHR Pharmaceutical (NASDAQ OHRP) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 2/15/2018 | Q1 2018 | ($0.07) | ($0.07) | | | View | N/A |  |
| 12/15/2017 | Q4 2017 | ($0.08) | ($0.08) | | | View | N/A | |
| 8/8/2017 | Q3 2017 | ($0.25) | ($0.07) | | | View | Listen | |
| 5/11/2017 | Q2 2017 | ($0.30) | ($0.21) | | | View | N/A | |
| 2/14/2017 | Q117 | ($0.19) | ($0.21) | | | View | Listen | |
| 12/22/2016 | Q4 2016 | ($0.24) | ($0.21) | | | View | N/A | |
| 8/9/2016 | Q3 2016 | ($0.23) | ($0.24) | | | View | N/A | |
| 5/10/2016 | Q2 | ($0.18) | ($0.17) | | | View | Listen | |
| 2/9/2016 | Q1 2016 | ($0.24) | ($0.20) | | | View | N/A | |
| 12/10/2015 | Q415 | ($0.20) | ($0.13) | | | View | Listen | |
| 8/6/2015 | Q3 2015 | ($0.21) | ($0.11) | | | View | N/A | |
| 5/11/2015 | Q215 | ($0.17) | ($0.12) | | | View | Listen | |
| 2/9/2015 | Q115 | ($0.20) | ($0.18) | | | View | N/A | |
| 12/22/2014 | | ($0.10) | ($0.12) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
OHR Pharmaceutical (NASDAQ:OHRP) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
OHR Pharmaceutical (NASDAQ OHRP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 17.40%
Institutional Ownership Percentage: 10.20%
OHR Pharmaceutical (NASDAQ OHRP) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/10/2017 | Orin Hirschman | Director | Buy | 142,858 | $0.70 | $100,000.60 | | |
| 4/10/2017 | Samuel Backenroth | CFO | Buy | 71,429 | $0.70 | $50,000.30 | 212,596 | |
| 6/20/2016 | Jason Scott Slakter | CEO | Buy | 8,786 | $2.85 | $25,040.10 | 917,954 | |
| 6/20/2016 | Samuel Backenroth | CFO | Buy | 2,468 | $2.84 | $7,009.12 | 138,709 | |
| 5/25/2016 | Jason Scott Slakter | CEO | Buy | 3,682 | $3.11 | $11,451.02 | 913,072 | |
| 5/24/2016 | Jason Scott Slakter | CEO | Buy | 28,068 | $3.15 | $88,414.20 | 885,841 | |
| 5/23/2016 | Samuel Backenroth | CFO | Buy | 2,500 | $3.17 | $7,925.00 | 136,362 | |
| 4/11/2016 | Jason Scott Slakter | CEO | Buy | 6,250 | $3.35 | $20,937.50 | 884,504 | |
| 3/7/2016 | Jason Scott Slakter | CEO | Buy | 6,250 | $3.63 | $22,687.50 | 873,527 | |
| 2/22/2016 | Jason Scott Slakter | CEO | Buy | 6,250 | $3.11 | $19,437.50 | 865,854 | |
| 1/19/2016 | Jason Scott Slakter | CEO | Buy | 6,250 | $3.62 | $22,625.00 | 865,754 | |
| 12/7/2015 | Jason Scott Slakter | CEO | Buy | 3,000 | $4.07 | $12,210.00 | 509,146 | |
| 11/3/2015 | Jason Scott Slakter | CEO | Buy | 13,350 | $3.00 | $40,050.00 | 77,923 | |
| 2/6/2015 | Irach B Taraporewala | CEO | Buy | 3,705 | $6.75 | $25,008.75 | | |
| 2/6/2015 | June Sherie Almenoff | Director | Buy | 6,000 | $6.75 | $40,500.00 | | |
| 2/6/2015 | Samuel Backenroth | CFO | Buy | 1,500 | $6.75 | $10,125.00 | | |
| 9/3/2014 | June Sherie Almenoff | Director | Buy | 2,200 | $8.08 | $17,776.00 | | |
| 7/2/2014 | Ira A Greenstein | Director | Buy | 1,000 | $8.40 | $8,400.00 | | |
| 6/26/2014 | June Sherie Almenoff | Director | Buy | 3,200 | $8.34 | $26,688.00 | | |
| 6/25/2014 | Thomas M Riedhammer | Director | Buy | 6,900 | $7.39 | $50,991.00 | | |
| 4/9/2014 | Ira A Greenstein | Director | Buy | 2,500 | $10.20 | $25,500.00 | | |
| 4/8/2014 | June Sherie Almenoff | Director | Buy | 5,500 | $10.25 | $56,375.00 | | |
(Data available from 1/1/2013 forward)
OHR Pharmaceutical (NASDAQ OHRP) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Zacks Investment Research Upgrades OHR Pharmaceutical (OHRP) to Buy
www.americanbankingnews.com - April 17 at 8:43 PM |
 | FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) To Contact The Firm
finance.yahoo.com - April 9 at 5:26 PM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Ohr Pharmaceutical, Inc. Investors and Sets a Lead Plaintiff Deadline of April 16, 2018 -- OHRP
finance.yahoo.com - April 9 at 5:26 PM |
| OHR Pharmaceutical (OHRP) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - April 6 at 6:29 PM |
| The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Ohr Pharmaceutical, Inc. Shareholders and a Lead Plaintiff Deadline of April 16, 2018
finance.yahoo.com - April 6 at 8:19 AM |
| OHR Pharmaceutical (OHRP) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 5 at 5:46 PM |
| OHR Pharmaceutical (OHRP) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 4 at 11:26 PM |
 | OHR LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses ...
globenewswire.com - March 27 at 5:18 PM |
| OHRP EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Ohr Pharmaceutical, Inc. and a Lead Plaintiff Deadline of April 16, 2018
finance.yahoo.com - March 26 at 5:23 PM |
| OHR LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Ohr Pharmaceutical, Inc. To Contact The Firm
finance.yahoo.com - March 26 at 5:23 PM |
 | EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Ohr ... - Business Wire (press release)
www.businesswire.com - March 21 at 8:41 AM |
| The Klein Law Firm Announces Commencement of a Class Action Filed on Behalf of Ohr Pharmaceutical, Inc ... - Business Wire (press release)
www.businesswire.com - March 21 at 8:41 AM |
| EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Ohr Pharmaceutical, Inc. Investors and Sets a Lead Plaintiff Deadline of April 16, 2018
finance.yahoo.com - March 20 at 5:21 PM |
| The Klein Law Firm Announces Commencement of a Class Action Filed on Behalf of Ohr Pharmaceutical, Inc. Shareholders and a Lead Plaintiff Deadline of April 16, 2018 (OHRP)
finance.yahoo.com - March 19 at 5:21 PM |
| DEADLINE ALERT: Brower Piven Reminds Investors of Upcoming Deadline in Class Action Lawsuit and Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Ohr Pharmaceutical, Inc. to Contact the Firm
finance.yahoo.com - March 16 at 6:33 PM |
| Innovate Biopharmaceuticals appoints June Almenoff, M.D., Ph.D. as Chief Operating Officer and Chief Medical Officer
finance.yahoo.com - March 13 at 8:18 AM |
| Short Interest in OHR Pharmaceutical Inc (OHRP) Drops By 27.7%
www.americanbankingnews.com - March 12 at 2:14 AM |
| OHR INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50000 ... - Business Wire (press release)
www.businesswire.com - March 9 at 8:14 AM |
| The Klein Law Firm Announces a Class Action Filed on Behalf of ... - GlobeNewswire (press release)
globenewswire.com - March 9 at 8:14 AM |
| OHRP INVESTOR ALERT: The Law Offices of Vincent Wong Notifies ... - Business Wire (press release)
www.businesswire.com - March 8 at 8:17 AM |
| OHRP INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Ohr Pharmaceutical, Inc. and a Lead Plaintiff Deadline of April 16, 2018
finance.yahoo.com - March 7 at 6:39 PM |
| SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
finance.yahoo.com - March 7 at 6:39 PM |
| OHRP SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class ... - GlobeNewswire (press release)
globenewswire.com - March 2 at 8:12 AM |
| OHRP SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Ohr Pharmaceutical, Inc. and a Lead Plaintiff Deadline of April 16, 2018
finance.yahoo.com - March 1 at 5:55 PM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Ohr Pharmaceutical, Inc. Investors and Sets a Lead Plaintiff Deadline of April 16, 2018
finance.yahoo.com - February 28 at 6:07 PM |
| INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Ohr Pharmaceutical, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
finance.yahoo.com - February 27 at 5:58 PM |
| The Klein Law Firm Reminds Investors of an Investigation Regarding Possible Violations of Federal Securities Laws by Ohr Pharmaceutical, Inc.
finance.yahoo.com - February 23 at 6:02 PM |
| The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Ohr Pharmaceutical, Inc. (OHRP)
finance.yahoo.com - February 20 at 5:50 PM |
| Robbins Arroyo LLP: Ohr Pharmaceutical, Inc. (OHRP) Misled Shareholders According to a Recently Filed Class Action - Business Wire (press release)
www.businesswire.com - February 18 at 8:14 AM |
| Robbins Arroyo LLP: Ohr Pharmaceutical, Inc. (OHRP) Misled Shareholders According to a Recently Filed Class Action
finance.yahoo.com - February 17 at 8:11 AM |
| Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Ohr Pharmaceutical, Inc.
finance.yahoo.com - February 15 at 5:23 PM |
| SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) To Contact Brower Piven Before The Lead Plaintiff Deadline
finance.yahoo.com - February 15 at 5:23 PM |
| OHRP SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Ohr Pharmaceutical, Inc.
finance.yahoo.com - February 15 at 5:23 PM |
| OHR Pharmaceutical (OHRP) Announces Earnings Results, Meets Estimates
www.americanbankingnews.com - February 15 at 10:08 AM |
| Ohr Pharmaceutical Reports Fiscal First Quarter 2018 Financial Results
finance.yahoo.com - February 15 at 9:25 AM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Ohr Pharmaceutical, Inc. Investors and Sets a Lead Plaintiff Deadline of April 16, 2018 -- OHRP
finance.yahoo.com - February 14 at 3:43 PM |
| Who Are The Major Shareholders Of OHR Pharmaceutical Inc (NASDAQ:OHRP)?
finance.yahoo.com - February 12 at 9:18 AM |
| OHR Pharmaceutical (OHRP) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - February 5 at 4:16 AM |
| OHR Pharmaceutical (OHRP) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - February 4 at 7:10 PM |
| OHR Pharmaceutical Inc (OHRP) Short Interest Up 47.8% in January
www.americanbankingnews.com - January 28 at 1:08 AM |
| Head to Head Contrast: ImmunoGen (IMGN) vs. Ohr Pharmaceuticals (OHRP)
www.americanbankingnews.com - January 9 at 9:38 AM |
| Zacks: Ohr Pharmaceuticals, Inc. (OHRP) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - January 6 at 5:18 AM |
| Ohr Pharmaceuticals (OHRP) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - January 5 at 11:22 PM |
 | Ohr Pharmaceutical (OHRP) Data from MAKO Study in Wet-AMD Did Not Meet Primary Efficacy Endpoint
www.streetinsider.com - January 5 at 4:16 PM |
| Ohr Pharmaceutical (OHRP) Reports Efficacy Results from the MAKO Study in Wet-AMD
www.streetinsider.com - January 5 at 10:35 AM |
| Here’s Why OHR Pharmaceutical Inc (OHRP) Shares Are Collapsing 80% Today
finance.yahoo.com - January 5 at 10:35 AM |
| Ohr Pharmaceuticals (OHRP) Downgraded by Roth Capital to "Neutral"
www.americanbankingnews.com - January 5 at 9:38 AM |
| Ohr Pharmaceuticals, Inc. (OHRP) Short Interest Update
www.americanbankingnews.com - December 30 at 2:00 AM |
| Ohr Pharmaceuticals, Inc. (OHRP) Given Average Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - December 22 at 11:28 AM |
| Zacks: Analysts Set $7.00 Target Price for Ohr Pharmaceuticals, Inc. (OHRP)
www.americanbankingnews.com - December 17 at 1:30 AM |
OHR Pharmaceutical (NASDAQ:OHRP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
OHR Pharmaceutical (NASDAQ:OHRP) Income Statement, Balance Sheet and Cash Flow Statement
OHR Pharmaceutical (NASDAQ OHRP) Stock Chart for Thursday, April, 19, 2018
Loading chart…
